CCT7

CCT7 is the eta subunit of the TRiC/CCT chaperonin complex and functions as a multi-client molecular chaperone that promotes the folding, stabilization, and trafficking of diverse protein substrates. It directly binds the intracellular loops and C-termini of nascent GPCRs (e.g., TPβ and β2AR) to prevent their aggregation and ensure cell-surface delivery, with a critical tryptophan residue (Trp334 of TPβ) mediating this interaction (PMID:27708139). Beyond host proteostasis, CCT7 stabilizes viral capsid proteins—FAdV-4 hexon and canine parvovirus VP2—and is required for viral replication (PMID:30691230, PMID:38384266). CCT7 also binds β-catenin to promote its nuclear translocation in Wnt signaling, thereby maintaining pluripotency in embryonic stem cells (PMID:41455472), interacts with TRAF6 to promote its ubiquitination and degradation thus suppressing autophagy and driving fibrosis (PMID:41947340), and its isolated apical domain inhibits tau aggregation via a fragmentation-based mechanism distinct from that of the CCT3 apical domain (PMID:40400346).

1. 2016 High

   Established that CCT7 functions beyond generic cytosolic chaperone activity by directly engaging GPCR intracellular domains to ensure their folding and surface delivery, answering how nascent membrane receptors avoid aggregation during biogenesis.

   Evidence Yeast two-hybrid, reciprocal co-IP with endogenous proteins, site-directed mutagenesis (Trp334), siRNA knockdown with surface-expression assay in mammalian cells

   PMID:27708139

   Open questions at the time

   • Whether other CCT subunits contribute independently to GPCR folding was not tested
   • Structural basis for the Trp334–CCT7 interface is unresolved
   • Generalizability to additional GPCR families beyond TPβ and β2AR remains untested
2. 2019 Medium

   Revealed that CCT7 chaperone function extends to viral substrates, as it binds and stabilizes FAdV-4 hexon protein and is required for viral replication, establishing CCT7 as a host factor co-opted by DNA viruses.

   Evidence Co-IP, RNAi knockdown and ectopic overexpression with hexon expression and viral replication assays in LMH cells

   PMID:30691230

   Open questions at the time

   • Whether the interaction occurs within an intact TRiC complex or via monomeric CCT7 was not determined
   • The binding interface on hexon was not mapped
   • Findings from a single lab in one avian cell line
3. 2024 High

   Extended the viral-client paradigm to a parvovirus: CCT7 stabilizes CPV capsid protein VP2 (residues 231–320), co-localizes with it cytoplasmically, and is required for CPV replication, demonstrating CCT7's role as a broad viral capsid chaperone.

   Evidence Yeast one-to-one assay, co-IP, confocal co-localization, VP2 truncation mapping, cycloheximide chase, RNAi and chemical inhibition (HSF1A), overexpression in mammalian cells

   PMID:38384266

   Open questions at the time

   • Whether CCT7 engagement with VP2 is TRiC-dependent or monomer-mediated is not resolved
   • Relevance to other parvoviruses or broader viral families is untested
4. 2025 Medium

   Defined a subunit-specific anti-aggregation mechanism: the isolated CCT7 apical domain inhibits tau aggregation while preserving the fragmentation kinetic model, in contrast to the CCT3 apical domain which shifts tau to a different kinetic regime—establishing that individual CCT subunits suppress amyloid formation through distinct mechanisms.

   Evidence In vitro tau aggregation kinetics, negative-stain EM, coarse-grained molecular dynamics simulations

   PMID:40400346

   Open questions at the time

   • Demonstrated only with isolated apical domain, not full-length CCT7 or intact TRiC
   • In vivo relevance to tauopathy models is not established
   • Single-lab, single-study finding
5. 2025 Medium

   Linked CCT7 to pluripotency maintenance: CCT7 depletion in ESCs disrupts telomere homeostasis, triggers DNA damage and epigenetic reprogramming toward totipotency, and this is mediated in part through CCT7 binding β-catenin to promote its nuclear translocation in Wnt signaling.

   Evidence siRNA/genetic depletion in ESCs, telomere length measurement, transcriptional profiling, co-IP of CCT7–β-catenin, β-catenin nuclear translocation assay

   PMID:41455472

   Open questions at the time

   • Whether β-catenin is a direct folding client or a signaling partner of CCT7 is unclear
   • Single lab; the relationship between telomere defects and Wnt signaling was not mechanistically resolved
   • Contribution of other CCT subunits (e.g., CCT5, also studied) versus CCT7-specific effects is not fully delineated
6. 2026 Medium

   Identified CCT7 as a pro-fibrotic factor that suppresses autophagy by binding TRAF6, promoting its ubiquitination and proteasomal degradation; epistasis experiments placed CCT7 upstream of TRAF6 in controlling autophagy and fibroblast activation.

   Evidence siRNA double-knockdown epistasis, co-IP, ubiquitination assay, autophagy flux markers, cell migration assay, in vivo joint contracture model in mice

   PMID:41947340

   Open questions at the time

   • Whether CCT7 acts as monomeric chaperone or within the TRiC holocomplex in this context is unknown
   • The E3 ligase mediating TRAF6 ubiquitination downstream of CCT7 was not identified
   • Single lab; generalizability to other fibrotic diseases not demonstrated

• It remains unresolved whether the non-canonical functions of CCT7 (GPCR folding, viral capsid stabilization, β-catenin translocation, TRAF6 regulation, tau anti-aggregation) occur through monomeric CCT7 or require the intact TRiC holocomplex, and no structural data exist for CCT7 bound to any of these client proteins.
• No high-resolution structure of CCT7 in complex with any identified client
• Monomeric versus holocomplex activity is systematically unresolved across all reported functions
• No unbiased proteomics identifying the full spectrum of CCT7-specific clients